Ascendis Pharma AS (ASND)
122.64
-1.74
(-1.40%)
USD |
NASDAQ |
Nov 21, 16:00
122.73
+0.09
(+0.07%)
After-Hours: 20:00
Ascendis Pharma Enterprise Value: 7.511B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 7.511B |
| November 20, 2024 | 7.615B |
| November 19, 2024 | 7.619B |
| November 18, 2024 | 7.473B |
| November 15, 2024 | 7.743B |
| November 14, 2024 | 7.609B |
| November 13, 2024 | 7.714B |
| November 12, 2024 | 7.812B |
| November 11, 2024 | 7.855B |
| November 08, 2024 | 7.612B |
| November 07, 2024 | 7.745B |
| November 06, 2024 | 7.913B |
| November 05, 2024 | 7.839B |
| November 04, 2024 | 7.698B |
| November 01, 2024 | 7.669B |
| October 31, 2024 | 7.522B |
| October 30, 2024 | 7.521B |
| October 29, 2024 | 7.758B |
| October 28, 2024 | 7.918B |
| October 25, 2024 | 7.970B |
| October 24, 2024 | 7.940B |
| October 23, 2024 | 7.813B |
| October 22, 2024 | 7.895B |
| October 21, 2024 | 7.871B |
| October 18, 2024 | 7.945B |
| Date | Value |
|---|---|
| October 17, 2024 | 7.751B |
| October 16, 2024 | 7.970B |
| October 15, 2024 | 7.790B |
| October 14, 2024 | 7.859B |
| October 11, 2024 | 7.884B |
| October 10, 2024 | 7.971B |
| October 09, 2024 | 7.909B |
| October 08, 2024 | 8.074B |
| October 07, 2024 | 8.497B |
| October 04, 2024 | 8.708B |
| October 03, 2024 | 8.605B |
| October 02, 2024 | 8.925B |
| October 01, 2024 | 8.943B |
| September 30, 2024 | 9.105B |
| September 27, 2024 | 9.086B |
| September 26, 2024 | 9.234B |
| September 25, 2024 | 9.169B |
| September 24, 2024 | 9.086B |
| September 23, 2024 | 9.188B |
| September 20, 2024 | 9.119B |
| September 19, 2024 | 9.243B |
| September 18, 2024 | 8.982B |
| September 17, 2024 | 8.851B |
| September 16, 2024 | 8.448B |
| September 13, 2024 | 7.281B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.265B
Minimum
May 11 2022
9.243B
Maximum
Sep 19 2024
6.454B
Average
6.348B
Median
Jan 14 2022
Enterprise Value Benchmarks
| Novo Nordisk AS | 453.33B |
| Evaxion Biotech AS | 3.461M |
| Trinity Biotech PLC | 91.30M |
| Biodexa Pharmaceuticals PLC | -3.355M |
| NuCana PLC | -11.87M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -109.10M |
| Revenue (Quarterly) | 63.61M |
| Total Expenses (Quarterly) | 170.00M |
| EPS Diluted (Quarterly) | -1.892 |
| Gross Profit Margin (Quarterly) | 80.63% |
| Profit Margin (Quarterly) | -171.5% |
| Earnings Yield | -6.61% |
| Normalized Earnings Yield | -6.609 |